Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Change in Account Payables (2016 - 2025)

Regenxbio has reported Change in Account Payables over the past 12 years, most recently at -$1.9 million for Q4 2025.

  • Quarterly results put Change in Account Payables at -$1.9 million for Q4 2025, down 161.26% from a year ago — trailing twelve months through Dec 2025 was -$2.3 million (down 682.19% YoY), and the annual figure for FY2025 was -$2.3 million, down 682.19%.
  • Change in Account Payables for Q4 2025 was -$1.9 million at Regenxbio, down from $694000.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for RGNX hit a ceiling of $16.8 million in Q1 2022 and a floor of -$14.9 million in Q2 2024.
  • Median Change in Account Payables over the past 5 years was $957000.0 (2023), compared with a mean of $555950.0.
  • Peak annual rise in Change in Account Payables hit 5926.98% in 2022, while the deepest fall reached 542.49% in 2022.
  • Regenxbio's Change in Account Payables stood at -$8.8 million in 2021, then skyrocketed by 121.65% to $1.9 million in 2022, then crashed by 36.03% to $1.2 million in 2023, then surged by 149.02% to $3.0 million in 2024, then plummeted by 161.26% to -$1.9 million in 2025.
  • The last three reported values for Change in Account Payables were -$1.9 million (Q4 2025), $694000.0 (Q3 2025), and $2.5 million (Q2 2025) per Business Quant data.